Core Viewpoint - Jingtai Holdings (02228) has seen a significant increase in stock price, rising over 4% today and nearly 50% in the month, driven by positive developments in its subsidiary ReviR's drug pipeline RTX-117 [1] Group 1: Company Developments - Jingtai Technology announced that its incubated company ReviR has achieved a milestone with the successful dual approval of RTX-117 in both the US and China [1] - ReviR will continue the clinical development of RTX-117, and Jingtai Technology is entitled to participate in sales revenue sharing and future licensing income from this pipeline [1] Group 2: Market Analysis - Guolian Minsheng Securities published a report stating that Jingtai Holdings has established a competitive moat in the AI pharmaceutical sector through its software and hardware technology accumulation and platform-based business model [1] - The clinical approval of RTX-117 marks the beginning of the value realization phase for its technology platform, with significant potential for performance elasticity and valuation restructuring as the collaboration pipeline expands [1]
晶泰控股再涨超4% ReviR创新药RTX-117获中美临床批件